Back تری‌هپتانوین AZB Glycerintriheptanoat German Triheptanoina Basque تری‌هپتانوین Persian Triheptanoïne French Trieptanoato di glicerina Italian トリヘプタノイン Japanese ଟ୍ରାଇହେପ୍ଟାନଏନ OR Trieptanoina Portuguese Triheptanoin Serbo-Croatian

Triheptanoin

Triheptanoin
Skeletal formula of triheptanoin
Space-filling model of the triheptanoin molecule
Clinical data
Pronunciation/traɪˈhɛptənɔɪn/
try-HEP-tə-noyn
Trade namesDojolvi
Other namesUX007
AHFS/Drugs.comProfessional Drug Facts
License data
Routes of
administration		By mouth
Drug classGlycerolipids
ATC code
Legal status
Legal status
Identifiers
  • 2,3-di(heptanoyloxy)propyl heptanoate or glyceryl triheptanoate
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.009.681 Edit this at Wikidata
Chemical and physical data
FormulaC24H44O6
Molar mass428.610 g·mol−1
3D model (JSmol)
  • CCCCCCC(=O)OCC(COC(=O)CCCCCC)OC(=O)CCCCCC
  • InChI=1S/C24H44O6/c1-4-7-10-13-16-22(25)28-19-21(30-24(27)18-15-12-9-6-3)20-29-23(26)17-14-11-8-5-2/h21H,4-20H2,1-3H3 ☒N
  • Key:PJHKBYALYHRYSK-UHFFFAOYSA-N ☒N

Triheptanoin, sold under the brand name Dojolvi, is a medication for the treatment of children and adults with molecularly confirmed long-chain fatty acid oxidation disorders (LC-FAOD).[2][3][4]

The most common adverse reactions include abdominal pain, diarrhea, vomiting, and nausea.[2][3][4]

Triheptanoin was approved for medical use in the United States in June 2020.[5][3][4]

Triheptanoin is a triglyceride that is composed of three seven-carbon (C7:0) fatty acids. These odd-carbon fatty acids are able to provide anaplerotic substrates for the TCA cycle. Triheptanoin is used clinically in humans to treat inherited metabolic diseases, such as pyruvate carboxylase deficiency and carnitine palmitoyltransferase II deficiency. It also appears to increase the efficacy of the ketogenic diet as a treatment for epilepsy.

Since triheptanoin is composed of odd-carbon fatty acids, it can produce ketone bodies with five carbon atoms, as opposed to even-carbon fatty acids which are metabolized to ketone bodies with four carbon atoms. The five-carbon ketones produced from triheptanoin are beta-ketopentanoate and beta-hydroxypentanoate. Each of these ketone bodies easily crosses the blood–brain barrier and enters the brain.

  1. ^ "Summary Basis of Decision (SBD) for Dojolvi". Health Canada. 23 October 2014. Retrieved 29 May 2022.
  2. ^ a b c "Dojolvi- triheptanoin liquid". DailyMed. 30 June 2020. Retrieved 24 September 2020.
  3. ^ a b c Cite error: The named reference Ultragenyx PR was invoked but never defined (see the help page).
  4. ^ a b c "Drug Trials Snapshots: Dojolvi". U.S. Food and Drug Administration. 30 June 2020. Retrieved 16 July 2020.
  5. ^ Cite error: The named reference FDA Dojolvi was invoked but never defined (see the help page).
From Wikipedia, the free encyclopedia · View on Wikipedia

Developed by Tubidy